Semaglutide Dosage and Mixing: What the Clinical Evidence Says

Why the graduated schedule exists: what STEP 1 showed

The 68-week STEP 1 trial, published in the New England Journal of Medicine, randomised over 1,900 adults with obesity to semaglutide 2.4 mg or placebo alongside lifestyle support. Participants who completed the full titration saw an average body-weight reduction of around 15%. That figure gets quoted often, but the part that tends to be skipped is why the slow ramp matters.

Semaglutide slows the rate at which the stomach empties and acts on appetite-regulating centres in the brain. Both effects are dose-dependent. Starting at a therapeutic maintenance dose from week one would hit those pathways hard before the body has had time to adjust, and the result is avoidable nausea, vomiting and diarrhoea. The titration schedule in the trial (and in the licensed product) is paced deliberately so that most of the gut-related discomfort stays manageable while the body settles in. Our guide to Wegovy doses walks through each stage in detail.

A common misconception worth clearing up gently: some people assume the early lower doses are delivering meaningful weight loss. They generally aren't. The starter dose is essentially a tolerability measure; the therapeutic effect builds as the dose increases. Knowing this can take some pressure off the early weeks, when progress may feel slow.

The licensed Wegovy schedule and the 7.2 mg approval

The standard Wegovy titration runs across roughly 16 weeks: 0.25 mg for four weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, reaching 2.4 mg as the maintenance dose. Each step is taken once weekly by subcutaneous injection into the abdomen, thigh or upper arm.

In January 2026, the MHRA approved a 7.2 mg maintenance dose for Wegovy, initially supplied as three 2.4 mg pens used in a single week. On 14 April 2026, the MHRA then approved a dedicated single-dose 7.2 mg pre-filled pen designed for once-weekly use. Trials reported average weight loss of around 20.7% over 72 weeks at the higher dose, narrowing the gap with tirzepatide (Mounjaro). Crucially, the titration pathway to 7.2 mg still begins at 0.25 mg, a patient doesn't skip to the higher target. If you want to understand what dose might be appropriate for your circumstances, speaking with a prescriber is the right starting point. You can also read more about the maximum semaglutide dosage and how the 7.2 mg approval changes the picture.

The licensed product for weight management is Wegovy. Ozempic contains the same active ingredient but is licensed for type 2 diabetes, not weight loss, and should not be used interchangeably.

Mixing queries and the compounded semaglutide distinction

Search results for "semaglutide mixing and dosage" often surface instructions for diluting or reconstituting semaglutide powder from vials. These relate to compounded or unlicensed products, not to the Wegovy pen available through UK-registered pharmacies. Wegovy comes pre-loaded; there is nothing to mix.

Compounded semaglutide is not approved by the MHRA for weight management, and the quality, concentration and sterility of such products cannot be verified. The MHRA has warned about counterfeit and unlicensed weight-loss injectables sold online, and some fake pens seized in the UK have been found to contain entirely different substances. Our Wegovy overview covers what a genuine, licensed supply chain looks like and how to check any online pharmacy on the GPhC register.

If you have seen a "mixing chart" or dosing guide for semaglutide vials, it is almost certainly referring to products that are not licensed in the UK for weight loss. For context on how legitimate dose schedules compare to what circulates online, the semaglutide dosage page sets out the licensed facts plainly.

What a prescriber considers when reviewing your dose

Dose titration is not automatic. A prescriber reviews whether a step-up is appropriate based on how well the current dose is being tolerated, any side effects, and whether the treatment is working as expected. If someone experiences persistent nausea at a particular dose, staying at that level for longer rather than advancing is entirely reasonable, and clinically supported.

The NICE appraisal of semaglutide for weight management (TA875) recommends stopping treatment if less than 5% weight loss has been achieved after six months at the maintenance dose. That benchmark informs how prescribers think about ongoing treatment decisions. It also underlines that dose management is an active, continuing conversation rather than a set-and-forget process.

At nume, a GPhC-registered Independent Prescriber (a real clinician, not a decision tree) reviews your consultation the same day, and that clinical oversight continues at every repeat. If you have questions about your current dose or want to explore whether Wegovy is suitable for you, our weight-loss treatment overview explains the options. For specific questions about how doses compare at different points in the schedule, the semaglutide 5 mg pen dosage page covers one of the commonly asked-about stages in full.

Treatment pricing, what a private prescription includes, and how costs compare across providers is all laid out on our Wegovy cost and pricing page, worth reading before deciding where to get treatment.